NHS England has announced that hundreds of babies have begun to be tested for over 200 genetic conditions as part of a study led by Genomics England. The Generation Study is evaluating the potential ...

The fourth annual QiC Dermatology Awards took place in Reading earlier this month and results can be found online here: QiC ...

The Clinical Trial Company (TCTC) targets medium size clinical trials and novel products which lack a classical road map to the market. Large CROs prioritise studies from the big pharma companies, for ...

We are a people activation agency. We use creativity to inspire positive change in both people and organisation they represent. We do this through; Events, Experiential, Content, Design, Film & ...

Highly encouraged to read this in Jim Nantz voice Hello friends. Consider a brand. Picture an experience. The Masters, one of ...

A leading global CRO, PRA is transforming clinical trials through our people, innovation and transparency. We serve clients across all phases of pharmaceutical and biotech drug development by ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been recommended by the European Medicines Agency’s human medicines committee to treat younger eosinophilic oesophagitis (EoE) patients. The Committee ...

Ipsen’s Iqirvo (elafibranor) has been conditionally approved by the European Commission (EC) to treat primary biliary cholangitis (PBC). The oral peroxisome proliferator-activated receptor (PPAR) ...

Risk taking is complicated. In business, ebullient entrepreneurs are lauded for putting their livelihood on the line and taking risks, while serial gamblers who do the same are frowned upon. When it ...

Wedgewood Communications has appointed Danielle Cranwell as president and global agency head to lead the evolution of the agency’s strategic vision and future direction. Cranwell brings more than two ...

The marketeer wants the agency it knows and trusts, not the ones on the list; the agency has spent a fortune on a pitch only to find the budget is a fraction of that suggested and the plan has changed ...

Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage study of its Keytruda (pembrolizumab) regimen in early-stage breast cancer.